Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.
Jonathan A. Chatzkel, MD
Advertisement
Articles by Jonathan A. Chatzkel, MD
Jonathan A. Chatzkel, MD, discusses the future treatment options in bladder cancer.
Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.
Advertisement
Latest Updated Articles
Dr. Chatzkel on Future Treatment Options in Bladder CancerFebruary 17th 2022
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS
5